[go: up one dir, main page]

SG11201909153UA - Peptides and combination thereof for use in the immunotherapy against cancers - Google Patents

Peptides and combination thereof for use in the immunotherapy against cancers

Info

Publication number
SG11201909153UA
SG11201909153UA SG11201909153UA SG11201909153UA SG 11201909153U A SG11201909153U A SG 11201909153UA SG 11201909153U A SG11201909153U A SG 11201909153UA SG 11201909153U A SG11201909153U A SG 11201909153UA
Authority
SG
Singapore
Prior art keywords
peptides
international
tiibingen
april
pct
Prior art date
Application number
Inventor
Marco Moreno Di
Sebastian Haen
Daniel Kowalewski
Markus Löffler
Annika Nelde
Hans-Georg Rammensee
Stefan Stevanovic
Nico Trautwein
Juliane Sarah Walz
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority claimed from PCT/EP2018/059109 external-priority patent/WO2018189148A1/en
Publication of SG11201909153UA publication Critical patent/SG11201909153UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIPO I PCT onion °nolo OH 1101 DID mil Imo oimIE (10) International Publication Number WO 2018/189148 Al (51) International Patent Classification: A61K 39/00 (2006.01) GO1N 33/50 (2006.01) C07K 14/47 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/059109 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10 2017 107 697.2 10 April 2017 (10.04.2017) DE 62/483,702 10 April 2017 (10.04.2017) US (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE). (72) Inventors: DI MARCO, Moreno; Memminger- strasse 18/1, 72072 Tiibingen (DE). HAEN, Se- bastian; Brombergstrasse 15, 72070 Tiibingen (DE). KOWALEWSKI, Daniel; Denzenbergstrasse 29, 72074 Tiibingen (DE). DUELER, Markus; Sandgrabenstrasse 20, 72119 Ammerbuch (DE). NELDE, Annika; Vik- tor-Renner-StraBe 27, 72074 Tiibingen (DE). RAM- MENSEE, Hans-Georg; Sommerhalde 3, 72070 Un- terjesingen (DE). STEVANOVIC, Stefan; Auf der Burg 3, 72074 Tilbingen (DE). TRAUTWEIN, Nico; Pelargusstrasse 2, 70180 Stuttgart (DE). WALZ, Juliane Sarah; Gartenstrasse 71, 72076 Tiibingen (DE). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (74) Agent: KRAUSS, Jan, B.; Boehmert & Boehmert, Pet- tenkoferstrasse 20 - 22, 80336 Munich (DE). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (54) Title: PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS (57) : The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. 1-1 00 71. 1-1 00 1-1 00 1-1 O C
SG11201909153U 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers SG11201909153UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10
DE102017107697 2017-04-10
PCT/EP2018/059109 WO2018189148A1 (en) 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers

Publications (1)

Publication Number Publication Date
SG11201909153UA true SG11201909153UA (en) 2019-10-30

Family

ID=62116819

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909153U SG11201909153UA (en) 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers
SG10202107869QA SG10202107869QA (en) 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202107869QA SG10202107869QA (en) 2017-04-10 2018-04-10 Peptides and combination thereof for use in the immunotherapy against cancers

Country Status (17)

Country Link
US (3) US20220332760A1 (en)
EP (2) EP3725327A3 (en)
JP (3) JP2020516681A (en)
KR (2) KR20240162609A (en)
CN (12) CN111548406A (en)
AU (2) AU2018251839B2 (en)
BR (1) BR112019020959A2 (en)
CA (1) CA3059644A1 (en)
CL (1) CL2019002880A1 (en)
CO (1) CO2019012077A2 (en)
CR (3) CR20210160A (en)
IL (1) IL269741A (en)
MA (2) MA51170A (en)
MX (1) MX2019012225A (en)
PE (1) PE20191711A1 (en)
PH (1) PH12019502308A1 (en)
SG (2) SG11201909153UA (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3725327A3 (en) * 2017-04-10 2021-01-20 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
CA3068852A1 (en) * 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
US12220402B2 (en) * 2020-06-03 2025-02-11 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
CN111978375B (en) * 2020-08-28 2022-10-04 深圳市乐土生物医药有限公司 Protein or polypeptide with cytotoxic T cell inducing ability
CN112010960A (en) * 2020-09-10 2020-12-01 热休(厦门)细胞生物科技有限公司 Tumor antigen complex in-vitro sensitized DC and T cell obtained tumor specific killer cell CTL and preparation method thereof
EP4340870A4 (en) * 2021-05-18 2024-11-20 Hung, Mien-Chie VACCINE, ITS USE AND VACCINE COCKTAIL AGAINST CANCER
CN114410638B (en) * 2022-01-24 2023-04-14 郑州大学 A nucleic acid aptamer and its application in the detection of esophageal cancer
CN117586344B (en) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 Antigenic peptide targeting FLT3-D835 mutation and application thereof in tumor immunotherapy
CN120712104A (en) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 Peptide vaccine against glioma and its use
CN116426532B (en) * 2023-06-08 2023-09-12 时夕(广州)生物科技有限公司 Targeting aptamer and application thereof
CN117552115B (en) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 Universal antigen peptide library for inducing tumor specific immune response and application thereof
CN118480561A (en) * 2024-05-30 2024-08-13 深圳大学总医院 New antigenic peptide generated by AML1-ETO fusion gene and application thereof
CN119390773B (en) * 2024-11-05 2025-08-12 绵阳市第三人民医院 A polypeptide with bidirectional regulation function of tumor immune microenvironment and its application

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2138662T3 (en) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc PRODUCTION OF ANTIBODY FRAGMENTS.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DK0879282T3 (en) 1996-01-17 2003-10-20 Imp College Innovations Ltd Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
MXPA01003344A (en) * 1998-09-30 2004-04-21 Corixa Corp Compositions and methods for wt1 specific immunotherapy.
AU6940700A (en) * 1999-08-26 2001-03-19 Amy P. N Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
CA2392764A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
JP4439808B2 (en) 2000-06-05 2010-03-24 アルター・バイオサイエンス・コーポレーション T cell receptor fusions and conjugates and methods for their use
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
US7553939B2 (en) * 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
CA2498854A1 (en) 2002-10-02 2004-04-15 Harald Kropshofer Novel mhc ii associated peptides
JP4436319B2 (en) 2002-10-09 2010-03-24 メディジーン リミテッド Single-chain recombinant T cell receptor
DE60327795D1 (en) 2002-11-09 2009-07-09 Immunocore Ltd T CELL RECEPTOR "DISPLAY"
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
KR20060013426A (en) 2003-05-30 2006-02-09 니뽄 신야쿠 가부시키가이샤 Oligo-double-stranded RNA which suppresses the expression of vaccin-2 and pharmaceutical composition containing it
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CN101035561A (en) * 2004-03-24 2007-09-12 特罗斯药品公司 Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
ES2334936T3 (en) 2005-04-20 2010-03-17 F. Hoffmann-La Roche Ag METHOD OF IDENTIFICATION OF EPITHOPES RELATED TO IMMUNOGENICITY IN BIOPHARMACOS.
ATE512160T1 (en) * 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-CELL EPITOPES FROM THE IMMATURE LAMININ RECEPTOR PROTEIN (ONCOFOETAL ANTIGEN) AND THEIR MEDICAL USES
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
ATE388164T1 (en) * 2005-09-05 2008-03-15 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES THAT BIND TO DIFFERENT CLASS II HUMAN LEUKOCYTE ANTIGENS
WO2007100607A2 (en) * 2006-02-24 2007-09-07 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides and methods of use
WO2007132461A2 (en) * 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
CA2694771A1 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2660248B1 (en) * 2007-07-27 2015-06-10 Immatics Biotechnologies GmbH Novel immunotherapy against brain tumors
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
UA104572C2 (en) * 2008-04-24 2014-02-25 Имматикс Байотекнолоджиз Гмбх Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules for vaccines
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (en) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Nucleic acids encoding chimeric polypeptides for systematic library identification
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6432114B2 (en) * 2014-12-25 2018-12-05 有限会社イムノ Drugs for inducing immune responses
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA45352A (en) * 2015-08-07 2018-06-13 Univ Birmingham IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY
US10159726B2 (en) * 2015-08-28 2018-12-25 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
EP3725327A3 (en) * 2017-04-10 2021-01-20 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (en) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods

Also Published As

Publication number Publication date
CR20190508A (en) 2020-01-08
BR112019020959A2 (en) 2020-05-05
EP3725327A2 (en) 2020-10-21
US20220356208A1 (en) 2022-11-10
EP3609530A1 (en) 2020-02-19
PE20191711A1 (en) 2019-11-28
JP2023100687A (en) 2023-07-19
IL269741A (en) 2019-11-28
CN111548406A (en) 2020-08-18
US20230346837A1 (en) 2023-11-02
CN111647062A (en) 2020-09-11
CN110494157A (en) 2019-11-22
JP2024174928A (en) 2024-12-17
CN111548405A (en) 2020-08-18
AU2018251839B2 (en) 2022-06-30
CN111533797A (en) 2020-08-14
EP3725327A3 (en) 2021-01-20
JP7551823B2 (en) 2024-09-17
CL2019002880A1 (en) 2020-03-13
CN111499715A (en) 2020-08-07
US20220332760A1 (en) 2022-10-20
MA49122A (en) 2021-03-24
CN111548404A (en) 2020-08-18
KR20190137829A (en) 2019-12-11
CA3059644A1 (en) 2018-10-18
CN111499716A (en) 2020-08-07
CN111533798A (en) 2020-08-14
CR20210160A (en) 2021-04-26
AU2022221503A1 (en) 2022-09-22
KR20240162609A (en) 2024-11-15
JP2020516681A (en) 2020-06-11
MX2019012225A (en) 2019-12-09
CN111533796A (en) 2020-08-14
CN111528539A (en) 2020-08-14
MA51170A (en) 2020-10-21
CO2019012077A2 (en) 2020-04-01
CN111499714A (en) 2020-08-07
CR20210159A (en) 2021-05-21
US11560405B2 (en) 2023-01-24
AU2018251839A1 (en) 2019-11-28
SG10202107869QA (en) 2021-08-30
PH12019502308A1 (en) 2020-10-26

Similar Documents

Publication Publication Date Title
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201806951TA (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201807300PA (en) Uterine cancer treatments
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201909058WA (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
SG11201806577UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201801756WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201811432WA (en) Rna for cancer therapy
SG11201809781PA (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
SG11201901176XA (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
SG11201808629UA (en) Immunotherapy against melanoma and other cancers
SG11201909265QA (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201906744VA (en) Core/shell structure platform for immunotherapy
SG11201901790YA (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof